Join CancerNetwork’s Integrative Oncology Tweet Chat

Article

CancerNetwork® will be hosting a tweet chat this Monday, November 16th, at 12 PM EST, that will feature real patient cases regarding the use of integrative oncology.

Join CancerNetwork® on Twitter this Monday, November 16th, at 12 PM EST, for a tweet chat on integrative oncology.

This discussion will feature real patient cases and present various treatment options for review, giving participants the opportunity to select what they believe is the best option for treatment.

The chat will be led by Linda E. Carlson, PhD, RPsych, the Enbridge Research Chair in Psychosocial Oncology, professor of Psychosocial Oncology in the department of Oncology in the Cumming School of Medicine at the University of Calgary, and adjunct professor in the Department of Psychology at the University of Calgary. Additionally, Carlson is also the director of Research and works as a clinical psychologist in the department of Psychosocial Resources at the Tom Baker Cancer Centre.

To participate in the chat, just follow the directions below.

integrative oncology tweet chat how to

tweet chat how to

Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
3 experts are featured in this series.
3 experts are featured in this series.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
4 experts are featured in this series.
6 experts are featured in this series.
Related Content
Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.

CHMP Recommends EU Approval for Durvalumab in Limited-Stage SCLC

Roman Fabbricatore
February 4th 2025
Article

Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Ariana Pelosci
February 4th 2025
Article

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Best Practices for Boosting the Enrollment of Underserved Populations in Cancer Clinical Trials

Best Practices for Boosting the Enrollment of Underserved Populations in Cancer Clinical Trials

Coral Omene, MD, PhD;Mariam Eskander, MD, MPH
February 3rd 2025
Article

Coral Omene, MD, PhD, and Mariam Eskander, MD, MPH, discuss how to continue engagement in clinical trial enrollment for underserved populations.

The PATHWAY HER2 test has been approved to identify patients with HER2-ultralow metastatic breast cancer who may benefit from treatment with T-DXd.

FDA OKs T-DXd Companion Diagnostic in HER2-Low Metastatic Breast Cancer

Roman Fabbricatore
February 3rd 2025
Article

The PATHWAY HER2 test has been approved to identify patients with HER2-ultralow metastatic breast cancer who may benefit from treatment with T-DXd.